Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Active:	No
Cancer Type:	Hematopoietic Malignancies Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT03677154
Trial Phases:	Phase I Phase II	Protocol IDs:	GO40554 (primary) NCI-2019-00169
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hoffmann-La Roche
NCI Full Details:	http://clinicaltrials.gov/show/NCT03677154

Summary

This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of
mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL)
immunochemotherapy in participants with a best response of stable disease or partial
response, or in elderly/unfit participants with previously untreated DLBCL, or
subcutaneous mosunetuzumab in combination with polatuzumab vedotin IV in elderly/unfit
participants with previously untreated DLBCL.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.